Role of Fenofibrate Use in Dyslipidemia and Related Comorbidities in the Asian Population: A Narrative Review
Diabetes & Metabolism Journal · 2024
DOI: 10.4093/dmj.2023.0168 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Diabetes & Metabolism Journal, 2024. Verfasst von Chaicharn Deerochanawong und 2 weiteren Autor:innen. Beteiligte Einrichtung: Diabetes and Endocrinology Unit, Department of Medicine, Rajavithi Hospital, College of Medicine, Rangsit University, Bangkok, Thailand. Hauptthemen laut MEDLINE: Fenofibrate, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Diabetes Mellitus, Type 2, Metabolic Syndrome. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Abbott Laboratories Ltd..
Abstract (Originalsprache)
Hypertriglyceridemia and decreased high-density lipoprotein cholesterol (HDL-C) persist despite statin therapy, contributing to residual atherosclerotic cardiovascular disease (ASCVD) risk. Asian subjects are metabolically more susceptible to hypertriglyceridemia than other ethnicities. Fenofibrate regulates hypertriglyceridemia, raises HDL-C levels, and is a recommended treatment for dyslipidemia. However, data on fenofibrate use across different Asian regions are limited. This narrative review summarizes the efficacy and safety data of fenofibrate in Asian subjects with dyslipidemia and related comorbidities (diabetes, metabolic syndrome, diabetic retinopathy, and diabetic nephropathy). Long-term fenofibrate use resulted in fewer cardiovascular (CV) events and reduced the composite of heart failure hospitalizations or CV mortality in type 2 diabetes mellitus. Fenofibrate plays a significant role in improving irisin resistance and microalbuminuria, inhibiting inflammatory responses, and reducing retinopathy incidence. Fenofibrate plus statin combination significantly reduced composite CV events risk in patients with metabolic syndrome and demonstrated decreased triglyceride and increased HDL-C levels with an acceptable safety profile in those with high CV or ASCVD risk. Nevertheless, care is necessary with fenofibrate use due to possible hepatic and renal toxicities in vulnerable individuals. Long-term trials and real-world studies are needed to confirm the clinical benefits of fenofibrate in the heterogeneous Asian population with dyslipidemia.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Diabetes and Endocrinology Unit, Department of Medicine, Rajavithi Hospital, College of Medicine, Rangsit University, Bangkok, Thailand.
- Division of Endocrinology and Metabolism, Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea.
- Department of Bioinformatics and Medical Engineering, Asia University, Taichung, Taiwan.
Förderung
- Abbott Laboratories Ltd.
Zitieren
APA
Deerochanawong, C., Kim, S. G., & Chang, Y. C. (2024). Role of Fenofibrate Use in Dyslipidemia and Related Comorbidities in the Asian Population: A Narrative Review. Diabetes & Metabolism Journal. https://doi.org/10.4093/dmj.2023.0168
Vancouver
Deerochanawong C, Kim SG, Chang YC. Role of Fenofibrate Use in Dyslipidemia and Related Comorbidities in the Asian Population: A Narrative Review. Diabetes & Metabolism Journal. 2024. doi:10.4093/dmj.2023.0168
BibTeX
@article{Deerochanawong2024,
author = {Deerochanawong, Chaicharn and Kim, Sin Gon and Chang, Yu-Cheng},
title = {Role of Fenofibrate Use in Dyslipidemia and Related Comorbidities in the Asian Population: A Narrative Review},
journal = {Diabetes & Metabolism Journal},
year = {2024},
doi = {10.4093/dmj.2023.0168}
}
EUVIMED